Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02401295 · ClinicalTrials.gov registry record · Phase 1
ATRA, Celecoxib, and Itraconazole as Maintenance
A Phase 1 study of Relapsed Multiple Myeloma, sponsored by University of Iowa.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
- 1
- Study location
NCT02401295: Completed Phase 1 study of Relapsed Multiple Myeloma, sponsored by University of Iowa.
NCT02401295 is a Phase 1 study of Relapsed Multiple Myeloma that has completed, run by University of Iowa. The registered enrollment target is 1 participants, below the 65-participant average among 5 other Relapsed Multiple Myeloma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02401295, a Phase 1 study of Relapsed Multiple Myeloma, has completed, sponsored by University of Iowa.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety and tolerability associated with the combination of ATRA/celecoxib/itraconazole as maintenance therapy given after an autologous stem cell transplant in relapsed multiple myeloma patients.
Conditions Studied
Interventions
- DRUG Celecoxib
- DRUG ATRA
- DRUG Itraconazole
Study Locations (1)
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2015-05 |
| Est. Completion | 2016-11 |
| Phase | Phase 1 |
What the finished NCT02401295 record still lists
NCT02401295 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 65-participant average among 5 other Relapsed Multiple Myeloma trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Relapsed Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Celecoxib is the first listed.
NCT02401295 reports a single indexed study location in Iowa.
Frequently Asked Questions
What is clinical trial NCT02401295 about?
NCT02401295 is a clinical study titled "ATRA, Celecoxib, and Itraconazole as Maintenance". The purpose of this study is to evaluate the safety and tolerability associated with the combination of ATRA/celecoxib/itraconazole as maintenance therapy given after an autologous stem cell transplant in relapsed multiple myeloma patients.
What is the current status of trial NCT02401295?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2015-05. Estimated completion is 2016-11.
What conditions does trial NCT02401295 study?
This clinical trial studies the following conditions: Relapsed Multiple Myeloma.
What interventions are being tested in trial NCT02401295?
The interventions under investigation include: Celecoxib (DRUG), ATRA (DRUG), Itraconazole (DRUG).
Who is sponsoring clinical trial NCT02401295?
This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02401295 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
-
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
RECRUITING · Phase 1
-
Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
-
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia